Report cover image

Interleukin Inhibitors for Psoriasis Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 128 Pages
SKU # APRC20260700

Description

Summary

According to APO Research, the global Interleukin Inhibitors for Psoriasis market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Interleukin Inhibitors for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Interleukin Inhibitors for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Interleukin Inhibitors for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Interleukin Inhibitors for Psoriasis include AbbVie Biotechnology, Almirall, Janssen Biotech, LEO Pharma, Novartis, Ortho Dermatologics, Samsung Bioepis, Sun Pharma and UCB, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Interleukin Inhibitors for Psoriasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Interleukin Inhibitors for Psoriasis.

The report will help the Interleukin Inhibitors for Psoriasis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Interleukin Inhibitors for Psoriasis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Interleukin Inhibitors for Psoriasis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Interleukin Inhibitors for Psoriasis Segment by Company

AbbVie Biotechnology
Almirall
Janssen Biotech
LEO Pharma
Novartis
Ortho Dermatologics
Samsung Bioepis
Sun Pharma
UCB
Dalian Yawei Pharmaceutical
China Medical System
Eli Lilly
Teva
Kyowa Kirin
Interleukin Inhibitors for Psoriasis Segment by Type

Interleukin-8 Inhibitors
Interleukin-23 Inhibitors
Interleukin-17 Inhibitors
Interleukin-12 Inhibitors
Other
Interleukin Inhibitors for Psoriasis Segment by Application

Hospital and Clinic
Retail Pharmacies
Other
Interleukin Inhibitors for Psoriasis Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin Inhibitors for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Interleukin Inhibitors for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin Inhibitors for Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Interleukin Inhibitors for Psoriasis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Interleukin Inhibitors for Psoriasis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Interleukin Inhibitors for Psoriasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

128 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Interleukin Inhibitors for Psoriasis Market Size (2020-2031)
2.2.2 Global Interleukin Inhibitors for Psoriasis Sales (2020-2031)
2.2.3 Global Interleukin Inhibitors for Psoriasis Market Average Price (2020-2031)
2.3 Interleukin Inhibitors for Psoriasis by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Interleukin-8 Inhibitors
2.3.3 Interleukin-23 Inhibitors
2.3.4 Interleukin-17 Inhibitors
2.3.5 Interleukin-12 Inhibitors
2.3.6 Other
2.4 Interleukin Inhibitors for Psoriasis by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital and Clinic
2.4.3 Retail Pharmacies
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Interleukin Inhibitors for Psoriasis Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Interleukin Inhibitors for Psoriasis Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Interleukin Inhibitors for Psoriasis Revenue of Manufacturers (2020-2025)
3.4 Global Interleukin Inhibitors for Psoriasis Average Price by Manufacturers (2020-2025)
3.5 Global Interleukin Inhibitors for Psoriasis Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Interleukin Inhibitors for Psoriasis, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Interleukin Inhibitors for Psoriasis, Product Type & Application
3.8 Global Manufacturers of Interleukin Inhibitors for Psoriasis, Established Date
3.9 Global Interleukin Inhibitors for Psoriasis Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 AbbVie Biotechnology
4.1.1 AbbVie Biotechnology Company Information
4.1.2 AbbVie Biotechnology Business Overview
4.1.3 AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.1.4 AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Product Portfolio
4.1.5 AbbVie Biotechnology Recent Developments
4.2 Almirall
4.2.1 Almirall Company Information
4.2.2 Almirall Business Overview
4.2.3 Almirall Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Almirall Interleukin Inhibitors for Psoriasis Product Portfolio
4.2.5 Almirall Recent Developments
4.3 Janssen Biotech
4.3.1 Janssen Biotech Company Information
4.3.2 Janssen Biotech Business Overview
4.3.3 Janssen Biotech Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Janssen Biotech Interleukin Inhibitors for Psoriasis Product Portfolio
4.3.5 Janssen Biotech Recent Developments
4.4 LEO Pharma
4.4.1 LEO Pharma Company Information
4.4.2 LEO Pharma Business Overview
4.4.3 LEO Pharma Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.4.4 LEO Pharma Interleukin Inhibitors for Psoriasis Product Portfolio
4.4.5 LEO Pharma Recent Developments
4.5 Novartis
4.5.1 Novartis Company Information
4.5.2 Novartis Business Overview
4.5.3 Novartis Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Novartis Interleukin Inhibitors for Psoriasis Product Portfolio
4.5.5 Novartis Recent Developments
4.6 Ortho Dermatologics
4.6.1 Ortho Dermatologics Company Information
4.6.2 Ortho Dermatologics Business Overview
4.6.3 Ortho Dermatologics Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Ortho Dermatologics Interleukin Inhibitors for Psoriasis Product Portfolio
4.6.5 Ortho Dermatologics Recent Developments
4.7 Samsung Bioepis
4.7.1 Samsung Bioepis Company Information
4.7.2 Samsung Bioepis Business Overview
4.7.3 Samsung Bioepis Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Samsung Bioepis Interleukin Inhibitors for Psoriasis Product Portfolio
4.7.5 Samsung Bioepis Recent Developments
4.8 Sun Pharma
4.8.1 Sun Pharma Company Information
4.8.2 Sun Pharma Business Overview
4.8.3 Sun Pharma Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Sun Pharma Interleukin Inhibitors for Psoriasis Product Portfolio
4.8.5 Sun Pharma Recent Developments
4.9 UCB
4.9.1 UCB Company Information
4.9.2 UCB Business Overview
4.9.3 UCB Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.9.4 UCB Interleukin Inhibitors for Psoriasis Product Portfolio
4.9.5 UCB Recent Developments
4.10 Dalian Yawei Pharmaceutical
4.10.1 Dalian Yawei Pharmaceutical Company Information
4.10.2 Dalian Yawei Pharmaceutical Business Overview
4.10.3 Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Product Portfolio
4.10.5 Dalian Yawei Pharmaceutical Recent Developments
4.11 China Medical System
4.11.1 China Medical System Company Information
4.11.2 China Medical System Business Overview
4.11.3 China Medical System Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.11.4 China Medical System Interleukin Inhibitors for Psoriasis Product Portfolio
4.11.5 China Medical System Recent Developments
4.12 Eli Lilly
4.12.1 Eli Lilly Company Information
4.12.2 Eli Lilly Business Overview
4.12.3 Eli Lilly Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Eli Lilly Interleukin Inhibitors for Psoriasis Product Portfolio
4.12.5 Eli Lilly Recent Developments
4.13 Teva
4.13.1 Teva Company Information
4.13.2 Teva Business Overview
4.13.3 Teva Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Teva Interleukin Inhibitors for Psoriasis Product Portfolio
4.13.5 Teva Recent Developments
4.14 Kyowa Kirin
4.14.1 Kyowa Kirin Company Information
4.14.2 Kyowa Kirin Business Overview
4.14.3 Kyowa Kirin Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Kyowa Kirin Interleukin Inhibitors for Psoriasis Product Portfolio
4.14.5 Kyowa Kirin Recent Developments
5 Global Interleukin Inhibitors for Psoriasis Market Scenario by Region
5.1 Global Interleukin Inhibitors for Psoriasis Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Interleukin Inhibitors for Psoriasis Sales by Region: 2020-2031
5.2.1 Global Interleukin Inhibitors for Psoriasis Sales by Region: 2020-2025
5.2.2 Global Interleukin Inhibitors for Psoriasis Sales by Region: 2026-2031
5.3 Global Interleukin Inhibitors for Psoriasis Revenue by Region: 2020-2031
5.3.1 Global Interleukin Inhibitors for Psoriasis Revenue by Region: 2020-2025
5.3.2 Global Interleukin Inhibitors for Psoriasis Revenue by Region: 2026-2031
5.4 North America Interleukin Inhibitors for Psoriasis Market Facts & Figures by Country
5.4.1 North America Interleukin Inhibitors for Psoriasis Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Interleukin Inhibitors for Psoriasis Sales by Country (2020-2031)
5.4.3 North America Interleukin Inhibitors for Psoriasis Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Interleukin Inhibitors for Psoriasis Market Facts & Figures by Country
5.5.1 Europe Interleukin Inhibitors for Psoriasis Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Interleukin Inhibitors for Psoriasis Sales by Country (2020-2031)
5.5.3 Europe Interleukin Inhibitors for Psoriasis Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Interleukin Inhibitors for Psoriasis Market Facts & Figures by Country
5.6.1 Asia Pacific Interleukin Inhibitors for Psoriasis Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Interleukin Inhibitors for Psoriasis Sales by Country (2020-2031)
5.6.3 Asia Pacific Interleukin Inhibitors for Psoriasis Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Interleukin Inhibitors for Psoriasis Market Facts & Figures by Country
5.7.1 South America Interleukin Inhibitors for Psoriasis Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Interleukin Inhibitors for Psoriasis Sales by Country (2020-2031)
5.7.3 South America Interleukin Inhibitors for Psoriasis Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Interleukin Inhibitors for Psoriasis Market Facts & Figures by Country
5.8.1 Middle East and Africa Interleukin Inhibitors for Psoriasis Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Interleukin Inhibitors for Psoriasis Sales by Country (2020-2031)
5.8.3 Middle East and Africa Interleukin Inhibitors for Psoriasis Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Interleukin Inhibitors for Psoriasis Sales by Type (2020-2031)
6.1.1 Global Interleukin Inhibitors for Psoriasis Sales by Type (2020-2031) & (K Units)
6.1.2 Global Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2020-2031)
6.2 Global Interleukin Inhibitors for Psoriasis Revenue by Type (2020-2031)
6.2.1 Global Interleukin Inhibitors for Psoriasis Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Type (2020-2031)
6.3 Global Interleukin Inhibitors for Psoriasis Price by Type (2020-2031)
7 Segment by Application
7.1 Global Interleukin Inhibitors for Psoriasis Sales by Application (2020-2031)
7.1.1 Global Interleukin Inhibitors for Psoriasis Sales by Application (2020-2031) & (K Units)
7.1.2 Global Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2020-2031)
7.2 Global Interleukin Inhibitors for Psoriasis Revenue by Application (2020-2031)
7.2.1 Global Interleukin Inhibitors for Psoriasis Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application (2020-2031)
7.3 Global Interleukin Inhibitors for Psoriasis Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Interleukin Inhibitors for Psoriasis Value Chain Analysis
8.1.1 Interleukin Inhibitors for Psoriasis Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Interleukin Inhibitors for Psoriasis Production Mode & Process
8.2 Interleukin Inhibitors for Psoriasis Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Interleukin Inhibitors for Psoriasis Distributors
8.2.3 Interleukin Inhibitors for Psoriasis Customers
9 Global Interleukin Inhibitors for Psoriasis Analyzing Market Dynamics
9.1 Interleukin Inhibitors for Psoriasis Industry Trends
9.2 Interleukin Inhibitors for Psoriasis Industry Drivers
9.3 Interleukin Inhibitors for Psoriasis Industry Opportunities and Challenges
9.4 Interleukin Inhibitors for Psoriasis Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.